Bridgeway Capital Management’s Orchestra BioMed OBIO Stock Holding History

Bridgeway Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348K	Buy	80,600 +10,000	+14%	+$40.9K	0.01%	940
2026 Q1	$300K	Buy	70,600 +45,600	+182%	+$194K	0.01%	935
2025 Q4	$104K	Hold	25,000	–	–	﹤0.01%	1121
2025 Q3	$62K	Hold	25,000	–	–	﹤0.01%	1153
2025 Q2	$67K	Buy	+25,000	New	+$73K	﹤0.01%	1114

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Bridgeway Capital Management's OBIO Position: Q2 2026 in Review

Bridgeway Capital Management increased its Orchestra BioMed (OBIO) stake by 14% in Q2 2026, buying an estimated $40.9K and bringing the position to 80,600 shares worth $348K. The position accounts for 0.01% of the portfolio, ranked #940.

Bridgeway Capital Management first reported a position in OBIO in Q2 2025 and has held it in 5 quarters since. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Bridgeway Capital Management held 80,600 shares of Orchestra BioMed worth $348K as of Q2 2026.
Bridgeway Capital Management bought 10,000 Orchestra BioMed shares in Q2 2026, an estimated $40.9K.
Orchestra BioMed made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #940 holding.
Bridgeway Capital Management first reported a position in Orchestra BioMed in Q2 2025 and has held it in 5 quarters since.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.